Cargando…

Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation

In 2014 a 66-year-old woman presented with anemia and an IgAk monoclonal spike. Bone marrow (BM) biopsy showed 80% lymphocytes and lymphoplasmacytoid cells. Computed Tomography (CT) scan documented neither adenopathy nor splenomegaly. Diagnosis of IgA lymphoplasmacytic lymphoma was made. After three...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quaglia, Francesca Maria, Rigolin, Gian Matteo, Saccenti, Elena, Negrini, Massimo, Volta, Eleonora, Dabusti, Melissa, Ciccone, Maria, Urso, Antonio, Laudisi, Michele, Cuneo, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736335/ https://www.ncbi.nlm.nih.gov/pubmed/31528323 http://dx.doi.org/10.4084/MJHID.2019.057

Ejemplares similares

Preneoplastic somatic mutations including MYD88(L265P) in lymphoplasmacytic lymphoma
por: Rodriguez, Sara, et al.
Publicado: (2022)

Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia
por: Cavallari, Maurizio, et al.
Publicado: (2018)

Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma
por: Baloda, Vandana, et al.
Publicado: (2022)

Correction: Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphoma
por: Baloda, Vandana, et al.
Publicado: (2022)

Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas
por: Shin, Sang-Yong, et al.
Publicado: (2016)

Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88(L265P) Mutation
por: Lynch, Ryan C., et al.
Publicado: (2017)

Schnitzler syndrome associated with MYD88 L265P mutation
por: Goodman, Aaron M., et al.
Publicado: (2019)

Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy
por: Martinelli, Sara, et al.
Publicado: (2016)

Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma
por: Lindholm, Kaleigh E., et al.
Publicado: (2021)

Determination of MYD88(L265P) mutation fraction in IgM monoclonal gammopathies
por: Bagratuni, Tina, et al.
Publicado: (2022)

Lymphoplasmacytic Lymphoma Presenting with Diarrhea and Joint Pain Which was Successfully Diagnosed by an MYD88 Mutation Analysis
por: Fukushima, Masaya, et al.
Publicado: (2017)

Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups
por: Cuneo, Antonio, et al.
Publicado: (2014)

Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance
por: Wang, James Q., et al.
Publicado: (2014)

MYD88 L265P mutation in intraocular lymphoma: A potential diagnostic marker
por: Narasimhan, Sandhya, et al.
Publicado: (2020)

MYD88(L265P) and MYD88(other) variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma
por: Qin, Yan, et al.
Publicado: (2023)

Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88(L265P) in Waldenström Macroglobulinemia
por: Kofides, Amanda, et al.
Publicado: (2021)

L265P Mutation of the MYD88 Gene Is Frequent in Waldenström’s Macroglobulinemia and Its Absence in Myeloma
por: Mori, Naoki, et al.
Publicado: (2013)

Droplet Digital PCR Assay for MYD88(L265P): Clinical Applications in Waldenström Macroglobulinemia
por: Lo Schirico, Mariella, et al.
Publicado: (2020)

Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features
por: Shuai, Wen, et al.
Publicado: (2020)

“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”
por: Cavallari, Maurizio, et al.
Publicado: (2017)

Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations
por: Rigolin, Gian Matteo, et al.
Publicado: (2016)

Erratum to: Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations
por: Rigolin, Gian Matteo, et al.
Publicado: (2016)

MYD88 L265P Mutations Are Correlated with 6q Deletion in Korean Patients with Waldenström Macroglobulinemia
por: Kim, Jung-Ah, et al.
Publicado: (2014)

Loss of TNFAIP3 enhances MYD88(L265P)-driven signaling in non-Hodgkin lymphoma
por: Wenzl, Kerstin, et al.
Publicado: (2018)

MYD88(L265P) Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation
por: Ferrante, Martina, et al.
Publicado: (2021)

IgA-producing lymphoplasmacytic lymphoma carrying the chromosomal abnormality t(8;14)
por: Gotoh, Yuta, et al.
Publicado: (2019)

An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness
por: Rigolin, Gian Matteo, et al.
Publicado: (2017)

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
por: Nelde, Annika, et al.
Publicado: (2016)

PB2403: THE FREQUENCY OF L265P MUTATION IN MYD88 GENE AT DIFFUSE LARGE B-CELL LYMPHOMA
por: Dubrovina, Anastasiya, et al.
Publicado: (2023)

Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia
por: Drandi, Daniela, et al.
Publicado: (2018)

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies
por: Çınar, Özcan, et al.
Publicado: (2021)

Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment
por: Schlevogt, Bernhard, et al.
Publicado: (2019)

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
por: Ansell, S M, et al.
Publicado: (2014)

Detection of the MYD88 p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma
por: Zorofchian, Soheil, et al.
Publicado: (2018)

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
por: Lee, Ju-Han, et al.
Publicado: (2017)

Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma
por: Yamagishi, Yuki, et al.
Publicado: (2021)

Synergistic cooperation and crosstalk between MYD88(L265P) and mutations that dysregulate CD79B and surface IgM
por: Wang, James Q., et al.
Publicado: (2017)

Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR
por: Niu, Jing, et al.
Publicado: (2020)

伴MyD88 L265P突变淋巴浆细胞疾病患者的临床特征分析
Publicado: (2016)

Effectiveness of digital PCR for MYD88(L265P) detection in vitreous fluid for primary central nervous system lymphoma diagnosis
por: Chen, Kun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lereh41jrn76lql7nch8b4a7ml